Fascial Closure Technique After Gynecologic Laparoscopic Surgery and Postoperative Pain
NCT ID: NCT04765306
Last Updated: 2022-05-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
123 participants
INTERVENTIONAL
2021-03-05
2022-04-14
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Fascial Closure Techniques Post-Operative Pain Laparoscopy
NCT03254056
Laparoscopic Incision Closure s in Obese Patients
NCT05622110
Laparoscopic Repair of Cesarean Scar Niche
NCT04307524
Effects of Tissue Sealers on Minor Laparoscopic Procedures Between Obstetrics and Gynecology Residents
NCT05710601
Optimal Method of Fascial Closure in High Risk Patients Undergoing Laparotomy
NCT02145052
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Traditional Direct Fascial Closure
At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed under traditional direct visualization without laparoscopic guidance using a single interrupted suture of 0-vicryl.
Traditional Direct Fascial Closure
Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
Fascial Closure Device
At the beginning of the laparoscopic procedure, all patients will receive 5 mL of 0.5% ropivacaine into each laparoscopic incision site. Patients in this group will have fascia closed using direct laparscopic visualization with the Carter-Thomason fascial closure device with a single interrupted suture of 0-vicryl.
Fascial Closure Device
Fascial closure using a fascial closure device under direct laparoscopic guidance.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Traditional Direct Fascial Closure
Fascial closure using traditional surgical instruments and suture without laparoscopic guidance.
Fascial Closure Device
Fascial closure using a fascial closure device under direct laparoscopic guidance.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Any patient undergoing laparoscopic gynecologic surgery with one left upper quadrant port site \> 10 mm via either robotic or traditional laparoscopic techniques for any indication including abnormal bleeding, pelvic pain, gynecologic cancer, uterine fibroids, etc. Procedures performed will include but not be limited to hysterectomy, bilateral or unilateral salpingoophorectomy, ovarian cystectomy, and pelvic floor support procedures.
* Patients willing and able to give informed consent.
* Patients capable and willing to return for follow up and complete pain diaries.
Exclusion Criteria
* Patients undergoing laparoscopic surgery that requires conversion to laparotomy.
* Patients undergoing laparoscopic surgery that does not require a port site \>10 mm.
18 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Jessica G Putman
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Jessica G Putman
Fellow Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Todd Boren, MD
Role: PRINCIPAL_INVESTIGATOR
University of Tennessee College of Medicine Gynecology Oncology
Jessica G Putman, MD
Role: STUDY_DIRECTOR
University of Tennessee Chattanooga Minimally Invasive Gynecologic Surgery Fellow
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Erlanger Baroness Hospital
Chattanooga, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
21-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.